Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to stop leukemia relapse after transplant

NCT ID NCT05088226

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Apr 28, 2026 · Last updated May 10, 2026 · Updated 3 times

Summary

This study tests whether adding two drugs, ruxolitinib and chidamide, to the standard chemo given before a stem cell transplant can lower the chance of leukemia coming back. It includes 50 people aged 12 to 65 with high-risk B-cell acute lymphoblastic leukemia who have a suitable donor. The main goal is to see how many patients stay cancer-free after the transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL BLOOD STEM CELL TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PERIPHERAL BLOOD STEM CELL TRANSPLANTATION